Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B) , protocol number NCT04509050

    This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      Less than 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 Years

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part A) , protocol number NCT04509050

    This two part study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      0 Years to 4 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      3 Years

    Contact us about this clinical Trial >
  • OtherRecruiting Location: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation

    A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation , protocol number NCT02725567

    The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation

    • Age:

      Maximum 24 months of Age

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in subject 6 through 11 years of Age with cystic fibrosis and F/MF genotypes

    A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in subject 6 through 11 years of Age with cystic fibrosis and F/MF genotypes , protocol number NCT04353817

    This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).

    • Age:

      6 Years through to 11 Years

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN) , protocol number BEGIN NCT04509050

    This two-part observational study will look at the effects of CFTR modulators on growth in infants and young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      0 Years to 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      3 Years

    Contact us about this clinical Trial >
  • Mucociliary ClearanceRecruiting Location: New Zealand

    Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis , protocol number AROENaC1001 NCT04375514

    The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety, tolerability, PK and efficacy of multiple doses of ARO-ENaC in patients with pulmonary cystic fibrosis.

    • Age:

      18 Years to 55 Years

    • Mutation(s):

      Any

    • FEV1% Predicted:

      between 40 and 90 percent-predicted

    • Number of Visits:

      15

    • Length of Participation:

      4 months

    Contact us about this clinical Trial >
  • Anti-InflammatoryNot yet recruiting Location: Brisbane

    A double blind, randomized, placebo controlled, cross-over trial investigating the effect of High Amylose Maize Starch (HAMS) supplementation on fecal microbiological and inflammatory outcomes in individuals with Cystic Fibrosis and Healthy Volunteers , protocol number ACTRN12618000283279

    Cystic Fibrosis (CF) is associated with a significant increase in gut dysbiosis. Exposure to multiple courses of antibiotics as well as an inherently inflammatory gut contributes to this. We have shown that there are significant differences between the CF gut and healthy volunteers in these respects. High amylose maize starch (HAMS) is a pre-biotic food stuff produced in such a way as to encourage the production of beneficial, anti-inflammatory compounds. In laboratory culture, we have shown that HAMS increases the production of these compounds. What is not clear however is whether this laboratory data translates to a clinical benefit. This study will attempt to understand the impact of HAMS supplementation on the bacteria in the gut and the ability of the gut to make anti-inflammatory compounds, in adult patients with CF as well as in healthy control subjects.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: Ohio, USA

    OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency (AzurRX AZ-CF2002) , protocol number NCT04375878

    This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      10

    • Length of Participation:

      8 weeks

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Multiple care centres across the US

    SIMPLIFY: Study to evaluate stopping inhaled hypertonic saline or dornase alfa in people with CF who are taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor , protocol number SIMPLIFY-IP-19 NCT04378153

    This study will test the effects and safety of stopping inhaled hypertonic saline or dornase alfa (Pulmozyme®) in teens and adults with CF who are also taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®). Trikafta® is intended to help CFTR function closer to normal, resulting in better clearance of mucus from the lungs. Inhaled hypertonic saline and dornase alfa are intended to thin airway surface liquid and improve clearance of mucus from the lungs. They are considered to be relatively burdensome therapies, so this study will look at the impact of stopping them in people who are also taking Trikafta®.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      60% or greater

    • Number of Visits:

      4

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryActive, not recruiting Location: Montreal, Toronto and Vancouver

    Phase 1b study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa. , protocol number Calithera CX-280-202 NCT04279769

    Patients will receive either CB-280 twice daily orally for 14 days or a placebo

    • Age:

      18 Years and older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40% and 90%

    • Number of Visits:

      Not specified

    • Length of Participation:

      2 weeks

    Contact us about this clinical Trial >
  • Displaying results 1-10 (of 201)
     |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|